In laboratory research evaluating growth-hormone-releasing hormone (GHRH) analogs, analytical precision is paramount to ensuring reproducible experimental outcomes. High-performance liquid chromatography (HPLC) serves as the definitive method for verifying the chemical purity, sequence integrity, and stability of synthetic CJC-1295. PX1 Research provides fully characterized, USA-manufactured research peptides accompanied by lot-specific HPLC and mass spectrometry documentation.
In laboratory research evaluating growth-hormone-releasing hormone (GHRH) analogs, analytical precision is paramount to ensuring reproducible experimental outcomes. High-performance liquid chromatography (HPLC) serves as the definitive method for verifying the chemical purity, sequence integrity, and stability of synthetic CJC-1295. PX1 Research provides fully characterized, USA-manufactured research peptides accompanied by lot-specific HPLC and mass spectrometry documentation.
CJC-1295 HPLC analysis is a reverse-phase analytical procedure used to separate, identify, and quantify the chemical purity of synthetic CJC-1295 peptide lots. By measuring the retention time and peak area against established chromatographic standards, HPLC confirms that the research peptide meets target purity specifications—typically exceeding 98%—prior to experimental reconstitution in vitro or in vivo research models.
Analytical chemists utilize Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to assess batch consistency and identify potential synthesis impurities, such as truncated peptide fragments, diastereomers, or oxidized species. When paired with Electrospray Ionization Mass Spectrometry (ESI-MS), HPLC provides comprehensive verification of both molecular weight and chemical identity. Researchers evaluating secretagogues must rely on verified analytical data to ensure that experimental observations stem solely from the target peptide rather than background contaminants or degradation products.
CJC-1295 is a synthetic 29-amino-acid peptide derivative of human growth-hormone-releasing hormone (GHRH 1-29). Native GHRH undergoes rapid enzymatic cleavage in vivo, primarily by dipeptidyl peptidase IV (DPP-IV), which cleaves the N-terminal Ala2 position within minutes. To resist enzymatic inactivation, the CJC-1295 sequence incorporates specific substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27.
In its long-acting variant, CJC-1295 incorporates a Drug Affinity Complex (DAC) reactive group—specifically, a maleimidopropionic acid linker covalently attached to the C-terminal lysine residue. This reactive functionality enables specific covalent binding to circulating serum albumin via a thioether linkage with Cys34. In contrast, modified GRF (1-29), often referred to as CJC-1295 without DAC, retains the four amino acid substitutions but lacks the C-terminal maleimide group. Accurate identification of these chemical structures via HPLC purity testing protocols is vital for ensuring experimental fidelity in receptor-binding assays.
Preclinical studies indicate that CJC-1295 acts as a selective agonist at the GHRH receptor located on pituitary somatotrophes. Binding to the GHRH receptor activates the Gs alpha subunit, stimulating intracellular adenylate cyclase and increasing cyclic adenosine monophosphate (cAMP) accumulation. This cascade promotes protein kinase A (PKA) activation, leading to the transcription and exocytosis of endogenous growth hormone (GH).
In rodent and non-human primate models, sustained GHRH receptor activation by CJC-1295 stimulates pulsatile secretion of endogenous GH, which subsequently induces hepatic expression and secretion of insulin-like growth factor 1 (IGF-1). Because IGF-1 plays a key regulatory role in cellular proliferation, protein translation, and tissue remodeling, researchers utilize CJC-1295 to study mechanisms underlying muscle repair, bone density preservation, and metabolic homeostasis in cell cultures and animal models. You can explore our catalog of research peptides to review synthesized GHRH analogs available for investigative work.
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) operates on hydrophobic interactions between the peptide molecules in the mobile phase and the non-polar stationary phase packed within a silica-based column (typically C18 or C8 chemistry). Because CJC-1295 features a specific hydrophobic profile derived from its amino acid sequence and optional DAC moiety, it elutes at a predictable retention window when subjected to a controlled gradient of water and organic modifier.
A standard RP-HPLC method for analyzing CJC-1295 uses a binary solvent system: Mobile Phase A (0.1% trifluoroacetic acid in LC-MS grade water) and Mobile Phase B (0.1% trifluoroacetic acid in LC-MS grade acetonitrile). As the gradient increases the proportion of Mobile Phase B over a set runtime (e.g., 20 to 30 minutes), CJC-1295 desorbs from the column stationary phase. Absorbance is monitored via a diode array detector (DAD) at 214 nm, the characteristic wavelength for peptide backbone amide bonds.
A pristine HPLC chromatogram for CJC-1295 displays a sharp, symmetrical single peak corresponding to the principal analyte, with baseline resolution separating it from minor synthesis byproducts. Peak purity is calculated using area-under-the-curve (AUC) integration, expressing the main peak area as a percentage of the total integrated peak area across the analytical run. PX1 Research enforces a strict purity threshold, requiring every lot to demonstrate ≥98% purity by AUC.
While HPLC quantifies chromatographic purity, liquid chromatography-mass spectrometry (LC-MS) confirms molecular identity by determining the exact mass-to-charge ratio (m/z). For CJC-1295 (without DAC, molecular formula C152H252N44O42, theoretical monoisotopic mass ~3367.9 Da), MS analysis displays characteristic multiply charged ions ([M+3H]3+, [M+4H]4+, [M+5H]5+). Observing the expected mass spectral pattern verifies that no unexpected truncations or sequence rearrangements occurred during solid-phase peptide synthesis (SPPS).
In vitro data demonstrate that CJC-1295 stimulates GH release in cultured primary anterior pituitary cells in a concentration-dependent manner. Because the peptide maintains structural stability against DPP-IV enzymatic cleavage, preclinical animal models exhibit extended plasma half-life compared to native GHRH(1-29). Studies in mice and rats show that a single administration elevates baseline GH levels for hours, driving sustained downstream IGF-1 transcription in hepatic tissue.
Researchers investigate these downstream effects to understand matrix synthesis in cartilage, collagen deposition during wound healing, and metabolic rate modulation. High-purity reference material certified by third-party laboratory testing is required for these studies to prevent confounding cellular responses caused by residual solvents, TFA salts, or truncated peptide sequences.
When designing preclinical protocol frameworks for growth factor signaling, investigators frequently compare multiple peptides within the secretagogue category. Sermorelin represents the un-modified native sequence GHRH(1-29) amide, exhibiting a rapid plasma clearance and short half-life due to DPP-IV susceptibility. Tesamorelin incorporates a hexenoyl moiety at the N-terminal trans-3-hexenoic acid position, enhancing enzymatic stability while retaining selectivity for the GHRH receptor. Meanwhile, Ipamorelin operates through a distinct pathway entirely, functioning as a selective agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a) rather than the GHRH receptor.
Combining a GHRH agonist like CJC-1295 with a GHS-R1a agonist like Ipamorelin in cell culture assays often reveals synergistic GH release mechanisms, as dual receptor activation triggers both cAMP-dependent and phospholipase C-dependent pathways. For broader mechanistic discussions on these pathways, reference our overview on growth hormone secretagogues.
Synthetic CJC-1295 is supplied as a lyophilized (freeze-dried) powder to maximize shelf-life stability. Lyophilized vials should be stored at -20°C or -80°C in a dry environment protected from light. Prior to reconstitution, vials should be allowed to equilibrate to room temperature to prevent condensation of moisture inside the container, which can accelerate hydrolytic degradation.
For laboratory reconstitution, researchers typically select sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile normal saline (0.9% NaCl), depending on assay compatibility. Gentle swirling without vortexing is recommended to fully dissolve the cake, as aggressive agitation introduces shear stress that can cause peptide aggregation. Reconstituted solutions should be aliquoted into polypropylene microcentrifuge tubes and stored at 2°C to 8°C for short-term experimentation or frozen at -80°C for long-term studies, avoiding repeated freeze-thaw cycles.
In addition to HPLC and mass spectrometry verification, high-purity research compounds must undergo bacterial endotoxin testing. Endotoxins, primarily lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria, can induce inflammatory responses in cell cultures and animal models, confounding experimental data and signaling pathways.
PX1 Research subjects every peptide lot to quantitative Limulus Amebocyte Lysate (LAL) assay testing to verify that endotoxin levels remain below strictly controlled thresholds (<0.01 EU/mg). Furthermore, manufacturing occurs in GMP-compliant facilities under rigid quality control standards, ensuring that researchers receive compounds free from heavy metals, residual synthesis reagents, and biological contaminants. Bulk institutional orders and lab accounts can be managed directly via our wholesale portal.
Navigating analytical peptide supply requires partnering with manufacturers who prioritize full transparency, batch traceability, and rigorous analytical verification. Every lot of CJC-1295 distributed by PX1 Research is synthesized in the USA and subjected to comprehensive third-party testing at an ISO 17025 accredited laboratory.
Each shipment includes a lot-specific Certificate of Analysis (COA) detailing RP-HPLC purity profiles, mass spectrometry verification, residual solvent analysis, and endotoxin levels. PX1 Research dispatches orders same-day from distribution centers in California and Arizona (Monday through Friday), ensuring rapid fulfillment to maintain laboratory supply chains without compromising quality.
What is the baseline purity specification for CJC-1295 verified by HPLC at PX1 Research?
PX1 Research mandates that all lots of CJC-1295 achieve a minimum of 98% chemical purity as quantified by Reverse-Phase HPLC area-under-the-curve (AUC) integration.
How does HPLC distinguish between CJC-1295 with DAC and CJC-1295 without DAC?
The addition of the Drug Affinity Complex (DAC) maleimide moiety increases the overall hydrophobicity and molecular mass of the peptide. On an RP-HPLC C18 column, CJC-1295 with DAC exhibits a distinctly longer retention time compared to CJC-1295 without DAC under identical gradient elution conditions.
Why is UV absorbance monitored at 214 nm during CJC-1295 HPLC testing?
Absorbance at 214 nm corresponds to the peptide bond (amide backbone) absorption wavelength. Monitoring at 214 nm allows universal detection of all peptide fragments, truncations, and impurities regardless of aromatic amino acid content.
What solvents are used in mobile phases for RP-HPLC analysis of CJC-1295?
Standard RP-HPLC analytical protocols utilize a gradient elution system comprising Mobile Phase A (0.1% trifluoroacetic acid in water) and Mobile Phase B (0.1% trifluoroacetic acid in acetonitrile).
What storage conditions maintain the HPLC-verified purity of lyophilized CJC-1295?
Lyophilized CJC-1295 should be stored at -20°C or -80°C in a desiccated, dark environment. Proper storage prevents moisture-induced hydrolysis and oxidative degradation over extended storage periods.
How does mass spectrometry complement HPLC data for CJC-1295?
While HPLC quantifies peptide concentration and relative purity percentages, mass spectrometry (MS) verifies the absolute molecular mass and ionization pattern, confirming correct amino acid sequence synthesis and absence of unintended modifications.
What endotoxin limits are enforced for PX1 Research CJC-1295 lots?
All peptide lots are verified by LAL testing to ensure endotoxin content is below 0.01 EU/mg, protecting cell cultures and animal models from endotoxin-induced inflammatory artifacts.
Can reconstituted CJC-1295 be re-analyzed via HPLC after freezing?
Yes, but repeated freeze-thaw cycles can induce peptide aggregation or degradation, which will manifest on an HPLC chromatogram as secondary artifact peaks or reduced primary peak area.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.